These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 32510611)

  • 1. A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment.
    Lombard L; Ye W; Nichols R; Jackson J; Cotton S; Joshi S
    Headache; 2020 Jul; 60(7):1325-1339. PubMed ID: 32510611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme.
    Hirata K; Ueda K; Ye W; Kim Y; Komori M; Jackson J; Cotton S; Rajan N; Treuer T
    BMC Neurol; 2020 Jul; 20(1):274. PubMed ID: 32641075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
    Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
    J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Inadequate Response to Acute Migraine Medication: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Munjal S; Buse DC; Fanning KM; Bennett A; Reed ML
    Headache; 2016 Nov; 56(10):1635-1648. PubMed ID: 27731896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
    Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
    J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China.
    Zhang L; Novick D; Zhong S; Li J; Walker C; Harrison L; Jackson J; Barlow S; Cotton S
    Pain Ther; 2023 Jun; 12(3):751-769. PubMed ID: 36944864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and predictors of costs among patients with migraine: evidence from the United States medical expenditure panel survey.
    Ford JH; Ye W; Nichols RM; Foster SA; Nelson DR
    J Med Econ; 2019 Sep; 22(9):849-858. PubMed ID: 30977712
    [No Abstract]   [Full Text] [Related]  

  • 9. Unsatisfactory response to acute medications does not affect the medication overuse headache development in pediatric chronic migraine.
    Frattale I; Ferilli MAN; Ursitti F; Sforza G; Monte G; Proietti Checchi M; Tarantino S; Mazzone L; Valeriani M; Papetti L
    J Headache Pain; 2024 Apr; 25(1):61. PubMed ID: 38649822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 3-month analysis of disability, quality of life, and disease course in patients with migraine.
    Raggi A; Leonardi M; Bussone G; D'Amico D
    Headache; 2013 Feb; 53(2):297-309. PubMed ID: 23094760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial.
    Schwedt TJ; Hentz JG; Sahai-Srivastava S; Spare NM; Martin VT; Treppendahl C; Digre K; Bennett NL; Birlea M; Watson D; Murinova N; Robert T; Dodick DW;
    Headache; 2021 Feb; 61(2):351-362. PubMed ID: 33432635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Acute Prescription Migraine Medication Use: Results From the CaMEO Study.
    Hutchinson S; Lipton RB; Ailani J; Reed ML; Fanning KM; Adams AM; Buse DC
    Mayo Clin Proc; 2020 Apr; 95(4):709-718. PubMed ID: 32247344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme.
    Ueda K; Ye W; Lombard L; Kuga A; Kim Y; Cotton S; Jackson J; Treuer T
    J Headache Pain; 2019 Jun; 20(1):68. PubMed ID: 31174464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allodynia Is Associated With Initial and Sustained Response to Acute Migraine Treatment: Results from the American Migraine Prevalence and Prevention Study.
    Lipton RB; Munjal S; Buse DC; Bennett A; Fanning KM; Burstein R; Reed ML
    Headache; 2017 Jul; 57(7):1026-1040. PubMed ID: 28603893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of increasing opioid use in the treatment of migraine: Results from the Migraine in America Symptoms and Treatment Study.
    Lipton RB; Buse DC; Dodick DW; Schwedt TJ; Singh P; Munjal S; Fanning K; Bostic Bs R; Reed ML
    Headache; 2021 Jan; 61(1):103-116. PubMed ID: 33326608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
    Tepper SJ; Dodick DW; Schmidt PC; Kellerman DJ
    Headache; 2019 Apr; 59(4):509-517. PubMed ID: 30698272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy (MOTS) trial.
    Shao SC; Hentz J; Shank P; Leonard M; Dodick DW; Schwedt TJ
    Headache; 2024 Jun; 64(6):632-642. PubMed ID: 38780360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of menstrual vs nonmenstrual migraine: a post hoc, within-woman analysis of the usual-care phase of a nonrandomized menstrual migraine clinical trial.
    MacGregor EA; Victor TW; Hu X; Xiang Q; Puenpatom RA; Chen W; Campbell JC
    Headache; 2010 Apr; 50(4):528-38. PubMed ID: 20236340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study.
    Lipton RB; Munjal S; Buse DC; Alam A; Fanning KM; Reed ML; Schwedt TJ; Dodick DW
    Headache; 2019 Sep; 59(8):1310-1323. PubMed ID: 31410844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.